Add-On Mavacamten Cuts Need for Septal Reduction in Obstructive HCM
WASHINGTON – Treatment with investigational mavacamten allowed patients with advanced obstructive hypertrophic cardiomyopathy (oHCM) to avoid septal reduction therapies (SRT), a researcher reported. In the VALOR-HCM study among 56 patients with documented oHCM who received add-on mavacamten to maximally-tolerated medical therapy, 17.9% met the composite endpoint (decision to move to SRT by week 16 or […]